Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4-MyD88 Complex

Area of Science:

• Immunology
• Molecular Biology
• Drug Discovery

Background:

• Dimethyl fumarate (DMF) is a therapeutic agent for multiple sclerosis and psoriasis.
• Its immunosuppressive effects are linked to covalent modification of cysteine residues.
• The specific protein targets and functional outcomes of DMF in immune cells are not fully understood.

Purpose of the Study:

• To elucidate the mechanism of action for dimethyl fumarate (DMF) in human immune cells.
• To identify the specific protein targets of DMF beyond the NRF2 pathway.
• To understand the functional consequences of DMF-protein interactions in innate immunity.

Main Methods:

• Chemical proteomics was employed to identify cellular targets of DMF.
• Functional assays were conducted to assess the impact of DMF on immune cell activity.
• Specific protein-protein interactions, such as IRAK4-MyD88, were investigated.

Main Results:

• Dimethyl fumarate (DMF) inhibits human plasmacytoid dendritic cell function independently of NRF2.
• Cysteine 13 of the innate immune kinase IRAK4 was identified as a primary target of DMF.
• DMF was shown to inhibit IRAK4-MyD88 interactions and subsequent cytokine production in a cysteine 13-dependent manner.

Conclusions:

• The study identifies IRAK4 as a key cellular target of dimethyl fumarate (DMF).
• DMF's mechanism involves blocking IRAK4-MyD88 interactions at cysteine 13.
• This identifies a critical druggable protein-protein interface for modulating innate immune responses.